

Ascendiant Capital Markets LLC serves as Financial Advisor on \$2,000,000 Private Placement for Outlook Therapeutics, Inc.

IRVINE, Calif., March 8, 2019 -- Ascendiant Capital Markets LLC ("Ascendiant") announced today the completion of a \$2,000,000 Private Placement for Outlook Therapeutics, Inc. (NasdaqCM: OTLK) of Cranbury, New Jersey.

Ascendiant served as a Financial Advisor on the transaction.

The key elements of the Private Placement transaction included extending the maturity of a debt instrument, lowering the interest rate, and adding a redemption feature, among other provisions.

About Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc. (NasdaqCM: OTLK) is a clinical-stage biopharmaceutical company focused on developing its lead clinical program, ONS-5010, a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration (wet AMD) and other retina diseases. ONS-5010 is currently in Phase 3 clinical trials outside the United States for patients suffering from wet AMD. For more information, please visit www.outlooktherapeutics.com.

About Ascendiant Capital Markets LLC

Ascendiant Capital Markets, LLC, based in Irvine, California, is a full-service investment banking, equity research, market making, and securities trading firm focused on public and private companies, and institutional, accredited, and strategic investors.

Ascendiant has led or participated in over \$1 billion in financing transactions, and the members of Ascendiant's Investment Banking Team have completed over 300 M&A transactions.

Ascendiant Capital Markets is registered with the United States Securities and Exchange Commission (SEC) as a broker-dealer, and is a member of the FINRA and SIPC.

For more information, please visit www.ascendiant.com or contact Bradley J. Wilhite, Co-Founder & Managing Partner, at 949.259.4949 or bwilhite@ascendiant.com

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.